Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.67 |
| ▸ | SRC | P12931 | 6/20 | 0.66 |
| ▸ | KDR | P35968 | 5/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | INSR | P06213 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161067 | 0.92 | EGFR (0.63) | EGFRSRCKDRRETFLT1 | |
| SCHEMBL158086 | 0.88 | ABCG2 (0.62) | EGFRSRCKDRKCNH2 | |
| SCHEMBL5825848 | 0.83 | KDR (0.54) | EGFRSRCKDRFLT1PDE10A | |
| SCHEMBL1808567 | 0.82 | TNNI3K (0.68) | EGFRSRCKDRFLT1 | |
| SCHEMBL15050423 | 0.81 | EGFR (0.54) | EGFRSRCKDRRETAURKA | |
| SCHEMBL15050417 | 0.81 | EGFR (0.56) | EGFRSRC | |
| SCHEMBL4890620 | 0.81 | EGFR (0.71) | EGFRSRCKDRRETFLT1 | |
| Hydrochloric Acid SCHEMBL6180313 | 0.81 | EGFR (0.70) | EGFRSRCKDRRETFLT1 | |
| SCHEMBL2920368 | 0.78 | PDGFRB (0.69) | PDE10A | |
| SCHEMBL6906281 | 0.77 | EGFR (0.86) | EGFRSRCKDRRETFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | ARROW THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | EIF2AK2, MAVS, IRF3 | EGFR 3952/4885SRC 3152/4885KDR 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.